Telomir Pharmaceuticals (NASDAQ: TELO) announced new research findings from The Ohio State University College of Veterinary Medicine showing that its lead compound, Telomir-Zn, produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, led by Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. These results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma, a strategy that could accelerate drug development by leveraging similarities between canine and human cancers.
Osteosarcoma is a rare but aggressive bone cancer that primarily affects children and young adults in humans, while it is relatively common in dogs, particularly large breeds. The comparable response of human and canine cell lines to Telomir-Zn at low concentrations suggests that the drug's mechanism may be conserved across species, making canine osteosarcoma a valuable model for studying human disease. This could allow Telomir to gather efficacy and safety data more rapidly and at lower cost than traditional human trials, potentially expediting the path to human clinical testing.
Telomir is in discussions with The Ohio State University College of Veterinary Medicine and is assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could support both veterinary development and translational advancement toward human osteosarcoma. If successful, it would provide proof-of-concept data that could inform human clinical trial design and attract additional investment or partnership interest.
While the osteosarcoma findings are promising, Telomir's immediate focus remains its triple-negative breast cancer (TNBC) program, which is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared Investigational New Drug (IND) application for advanced or metastatic TNBC. TNBC is an aggressive subtype of breast cancer with limited treatment options, and Telomir-Zn's novel mechanism of modulating intracellular metal homeostasis and epigenetic regulation represents a potential new approach for patients who do not respond to existing therapies.
The dual potential of Telomir-Zn in both oncology and rare diseases underscores the broad applicability of the company's platform. For investors, the osteosarcoma data provide an additional catalyst that could expand the value proposition beyond the TNBC program. The use of canine models is particularly noteworthy because it aligns with the FDA's support for comparative oncology, which encourages the study of naturally occurring cancers in animals to inform human drug development.
For more details, see the full press release at https://nnw.fm/laeGH. Additional information about Telomir Pharmaceuticals is available in the company's newsroom at https://nnw.fm/TELO. NetworkNewsWire maintains a specialized communications platform for financial news and content distribution, with more information at https://www.NetworkNewsWire.com.
